bcg-publication-2.jpg

Digital Therapeutics 2.0, Part Two: Connecting Users to Outcomes

Once a digital therapeutics (DTx) company has determined the kind of value its software as a medical device (SaMD) provides, it needs to figure out which regulatory and commercialization strategies make the most sense.